ArticleCornea2022
Refractive Shifts and Changes in Corneal Curvature Associated With Antibody-Drug Conjugates.
Article in Cornea, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 22 citations in OpenAlex.
- Review
- Bench-to-Bedside Perspectives on Ocular Toxicity of Antibody-Drug Conjugates: Toxicology, Clinical Management and Molecule Optimization.Pharmaceutical research · 2026Review
- Ocular toxicity associated with antibody-drug conjugates in cancer therapy: a comprehensive review.Frontiers in immunology · 2026Review
- Treatment with Mirvetuximab-Soravtansin-first clinical experience in advanced ovarian cancer in a comprehensive cancer center.Frontiers in oncology · 2026Article
- [Corneal events with mirvetuximab soravtansine : A review of ocular surface events associated with the tubulin-acting antibody-drug conjugate, mirvetuximab soravtansine].Die Ophthalmologie · 2025Review
- Intraepithelial corneal deposits associated with Mirvetuximab soravtansine use for platinum-resistant ovarian cancer.American journal of ophthalmology case reports · 2025Article
- Dehydrated amniotic membrane patch for the treatment of an ocular event secondary to mirvetuximab soravtansine-gynx (MIRV) therapy.Gynecologic oncology reports · 2024Article
- Ocular side effects of anticancer agents used in the treatment of gynecologic cancers.Gynecologic oncology · 2024Review
- Incidence and Mitigation of Corneal Pseudomicrocysts Induced by Antibody-Drug Conjugates (ADCs).Current ophthalmology reports · 2024Article
- Ocular Surface Side Effects of Novel Anticancer Drugs.Cancers · 2024Review
- Ocular adverse events associated with antibody-drug conjugates in oncology: a pharmacovigilance study based on FDA adverse event reporting system (FAERS).Frontiers in pharmacology · 2024Article
- Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine.Gynecologic oncology reports · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
purposeAntibody-drug conjugates (ADCs) are a class of cancer drug wherein some are associated with corneal abnormalities, but there is a dearth of published information on refractive shifts in patients receiving ADCs. Here, we evaluated the dynamics of refractive error and keratometry readings in patients with ADC-related keratopathy and microcyst-like epithelial changes (MECs).
methodsThis study is a retrospective case series including 58 eyes of 29 patients with ADC-related keratopathy from a single tertiary care cancer referral center (MSKCC). One eye (29 total) was randomly assigned for statistical analysis. In addition, a subset analysis of MEC location-refractive error correlation was performed on 20 eyes. Clinical records including slitlamp examination, indirect ophthalmoscopy, calculated spherical equivalence (SE), keratometry, and visual acuity were recorded at baseline, during, and off treatment.
resultsA subset analysis of MEC location-refractive error correlation of 20 eyes revealed the following: Peripheral MECs were significantly associated with hyperopic shifts (P value < 0.001) and paracentral/central associated with myopic shifts (P value < 0.001). In the full cohort and on drug, the greatest change in SE from baseline was myopic (68%, as high as -4.75 D) and hyperopic (32%, as much as +3.75 D). Eighty-nine percent had a change in vision from baseline while on drug, but at the 3-month follow-up off drug, SE and vision returned to baseline in 33% and 82% of eyes.
conclusionsPeripheral MECs were significantly associated with hyperopic shifts, and paracentral/central MECs were associated with myopic shifts. While on drug, most eyes had a myopic refractive shift, which corresponded with corneal steepening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.